[go: up one dir, main page]

NO20054414L - Dihydropteridinones, methods for their preparation and their use as medicines - Google Patents

Dihydropteridinones, methods for their preparation and their use as medicines

Info

Publication number
NO20054414L
NO20054414L NO20054414A NO20054414A NO20054414L NO 20054414 L NO20054414 L NO 20054414L NO 20054414 A NO20054414 A NO 20054414A NO 20054414 A NO20054414 A NO 20054414A NO 20054414 L NO20054414 L NO 20054414L
Authority
NO
Norway
Prior art keywords
dihydropteridinones
medicines
preparation
methods
isomers
Prior art date
Application number
NO20054414A
Other languages
Norwegian (no)
Other versions
NO332538B1 (en
Inventor
Flavio Solca
Christian Eickmeier
Matthias Hoffmann
Gisela Schnapp
Matthias Grauert
Steffen Breitfelder
Martin Steegmaier
Jens Juergen Quant
Trixi Brandl
Anke Baum
Florian Colbatzky
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20054414L publication Critical patent/NO20054414L/en
Publication of NO332538B1 publication Critical patent/NO332538B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse angår nye dihydropteridinoner med den generelle formel (I) hvor gruppene L og R1- R5 har betydningene som er angitt i kravene og beskrivelsen, isomerene derav, fremgangsmåter for fremstilling av disse dihydropteridinonene og anvendelsen av dem som farmasøytiske preparater.The present invention relates to novel dihydropteridinones of general formula (I) wherein the groups L and R 1 to R 5 have the meanings given in the claims and description, their isomers, processes for preparing these dihydropteridinones and their use as pharmaceutical preparations.

NO20054414A 2003-02-26 2005-09-23 Dihydropteridinones, method of preparation, use thereof as medicaments and use thereof for the manufacture of pharmaceutical preparations for the treatment of disease NO332538B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2003/001935 WO2004076454A1 (en) 2003-02-26 2003-02-26 Dihydropteridinones, method for the production and use thereof in the form of drugs

Publications (2)

Publication Number Publication Date
NO20054414L true NO20054414L (en) 2005-09-23
NO332538B1 NO332538B1 (en) 2012-10-15

Family

ID=32921552

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054414A NO332538B1 (en) 2003-02-26 2005-09-23 Dihydropteridinones, method of preparation, use thereof as medicaments and use thereof for the manufacture of pharmaceutical preparations for the treatment of disease

Country Status (26)

Country Link
EP (1) EP1599478B1 (en)
JP (1) JP3876265B2 (en)
KR (1) KR100983462B1 (en)
CN (2) CN101200457A (en)
AT (1) ATE361924T1 (en)
AU (1) AU2003215591B2 (en)
BR (1) BR0318145A (en)
CA (1) CA2517020C (en)
CY (1) CY1106752T1 (en)
DE (1) DE50307267D1 (en)
DK (1) DK1599478T3 (en)
EA (1) EA008778B1 (en)
ES (1) ES2287583T3 (en)
HR (1) HRP20050735B1 (en)
IL (1) IL170419A (en)
ME (1) ME00376B (en)
MX (1) MXPA05009068A (en)
NO (1) NO332538B1 (en)
NZ (1) NZ542498A (en)
PL (1) PL226417B1 (en)
PT (1) PT1599478E (en)
RS (1) RS52386B (en)
SI (1) SI1599478T1 (en)
TW (1) TWI313600B (en)
UA (1) UA80743C2 (en)
WO (1) WO2004076454A1 (en)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
JP2007514759A (en) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド Kinase inhibitor
DE102004029784A1 (en) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
DE102004033670A1 (en) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pyridodihydropyrazinone, process for its preparation and its use as a medicament
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
JP2008510734A (en) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド Kinase inhibitor
EP1630163A1 (en) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, methods for their preparation and their use as drugs
EP1632493A1 (en) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridine derivatives, methods for their preparation and their use as drugs
EP1784406A1 (en) * 2004-08-27 2007-05-16 Boehringer Ingelheim International GmbH Dihydropteridinones, process for their preparation and their use as drugs
DE602005023333D1 (en) 2004-10-15 2010-10-14 Takeda Pharmaceutical KINASE INHIBITORS
DE102004058337A1 (en) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1948180B1 (en) 2005-11-11 2013-03-13 Boehringer Ingelheim International GmbH Combination treatment of cancer comprising egfr/her2 inhibitors
AU2012256410B2 (en) * 2006-02-08 2016-04-28 Boehringer Ingelheim International Gmbh Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
NZ570530A (en) 2006-02-14 2011-09-30 Vertex Pharma Pharmaceutical compositions comprising 6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4)diazepine derivatives
CN101448830A (en) * 2006-05-19 2009-06-03 阿斯利康(瑞典)有限公司 Dihydropteridine compounds as anti proliferative agents
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
BRPI0719883A2 (en) 2006-10-09 2015-05-05 Takeda Pharmaceutical Kinase Inhibitors
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
KR20140104060A (en) 2006-10-19 2014-08-27 시그날 파마소티칼 엘엘씨 Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
WO2008076392A2 (en) * 2006-12-14 2008-06-26 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
NZ577798A (en) 2006-12-21 2012-04-27 Vertex Pharma 5-cyano-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
EP1953163A1 (en) * 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
EP2185559A1 (en) * 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
EP2610256B1 (en) 2007-09-28 2016-04-27 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
US20090291938A1 (en) * 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
WO2009071480A2 (en) * 2007-12-04 2009-06-11 Nerviano Medical Sciences S.R.L. Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
GB0807452D0 (en) * 2008-04-24 2008-05-28 Chroma Therapeutics Ltd PLK inhibitors
WO2010008459A1 (en) * 2008-06-23 2010-01-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
WO2010021750A2 (en) 2008-08-21 2010-02-25 The Johns Hopkins University Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
WO2010025073A1 (en) * 2008-08-28 2010-03-04 Takeda Pharmaceutical Company Limited Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
CA2745295C (en) 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
EP3255047B1 (en) * 2009-01-06 2021-06-30 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and uses in treating disorders
SG10201405826RA (en) 2009-06-17 2014-12-30 Vertex Pharma Inhibitors of influenza viruses replication
PT2477987T (en) 2009-09-14 2018-03-13 Gilead Sciences Inc Modulators of toll-like receptors
CN102020643A (en) 2009-09-22 2011-04-20 上海恒瑞医药有限公司 dihydropteridine ketone derivative, and preparation method and medicinal application thereof
MX2012003484A (en) 2009-09-25 2012-04-20 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors.
CN103492391A (en) 2009-09-25 2014-01-01 沃泰克斯药物股份有限公司 Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
MY177695A (en) 2009-10-26 2020-09-23 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
CA2783258A1 (en) * 2009-12-23 2011-06-30 Elan Pharmaceuticals, Inc. Pteridinones as inhibitors of polo-like kinase
EP2536725B1 (en) * 2010-02-17 2015-10-28 Boehringer Ingelheim International GmbH Dihydropteridinones, method for production and use thereof
CN102190669A (en) * 2010-03-19 2011-09-21 江苏恒瑞医药股份有限公司 Dihydro pteridinone derivatives, preparation method thereof and application thereof in medicines
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US8546566B2 (en) * 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
RU2013132681A (en) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед INFLUENZA VIRUS REPLICATION INHIBITORS
US20130131069A1 (en) 2011-05-13 2013-05-23 Boehringer Ingelheim International Gmbh Method for treatment of solid malignancies including advanced or metastatic solid malignancies
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
UA118010C2 (en) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед INFLUENCES OF INFLUENZA VIRUS REPLICATION
WO2013059396A2 (en) 2011-10-19 2013-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
EP2776444A4 (en) * 2011-11-10 2015-07-22 Osi Pharmaceuticals Llc Dihydropteridinones
MX363034B (en) 2011-12-02 2019-03-06 Signal Pharm Llc PHARMACEUTICAL COMPOSITIONS OF 7- (6- (2-HIDROXIPROPAN-2-IL) PIRIDIN- 3-IL) -1 - ((TRANS) -4-METOXICICLOHEXIL) -3,4-DIHYDROPIRAZINE [2,3-B] PI RAZIN -2 (1H) -ONA, A SOLID FORM OF THE SAME AND METHODS OF ITS USE.
JP5807750B2 (en) * 2012-01-05 2015-11-10 トヨタ自動車株式会社 Fastening device and fastening method
US8865716B2 (en) 2012-02-23 2014-10-21 Boehringer Ingelheim International Gmbh Dihydropteridinones II
US9006226B2 (en) 2012-02-23 2015-04-14 Boehringer Ingelheim International Gmbh Dihydropteridinones I
EA028462B1 (en) 2012-02-24 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Methods for treating advanced non-small cell lung cancer using tor kinase inhibitor combination therapy
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US20140154304A1 (en) 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib
ES2638179T3 (en) 2013-01-16 2017-10-19 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
EP2958919B1 (en) * 2013-02-21 2019-05-22 Boehringer Ingelheim International GmbH Dihydropteridinones i
JP6072308B2 (en) * 2013-02-21 2017-02-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dihydropteridinone II
JP6382945B2 (en) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー Cancer treatment with dihydropyrazino-pyrazine
WO2014172431A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
KR102459285B1 (en) 2013-04-17 2022-10-27 시그날 파마소티칼 엘엘씨 PHARMACEUTICAL FORMULATIONS, PROCESSES, SOLID FORMS AND METHODS OF USE RELATING TO 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN-2(1H)-ONE
TWI654979B (en) 2013-04-17 2019-04-01 美商標誌製藥公司 Method of treating cancer using TOR kinase inhibitor combination therapy
WO2014172432A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
KR102221029B1 (en) 2013-04-17 2021-02-26 시그날 파마소티칼 엘엘씨 Treatment of cancer with dihydropyrazino-pyrazines
CN113831345A (en) 2013-05-29 2021-12-24 西格诺药品有限公司 Pharmaceutical compositions of dihydropyrazinopyrazine compounds, solid forms thereof and their use
JP2016525532A (en) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Treatment of myelodysplastic syndrome
PT3068776T (en) 2013-11-13 2019-08-26 Vertex Pharma Inhibitors of influenza viruses replication
WO2015073481A1 (en) 2013-11-13 2015-05-21 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
KR20160111520A (en) * 2014-01-31 2016-09-26 다나-파버 캔서 인스티튜트 인크. Dihydropteridinone derivatives and uses thereof
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
CN104003989B (en) * 2014-05-26 2015-11-11 苏州明锐医药科技有限公司 Fu Lasai for and the preparation method of intermediate
MA40238A (en) 2014-07-11 2017-05-17 Gilead Sciences Inc Modulators of toll-like receptors for the treatment of hiv
JP2017520603A (en) 2014-07-14 2017-07-27 シグナル ファーマシューティカルズ，エルエルシー Method for treating cancer using substituted pyrrolopyrimidine compound and composition thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
RU2017104897A (en) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. DIAZEPANE DERIVATIVES AND THEIR APPLICATIONS
WO2016022970A1 (en) * 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
BR102015023450A2 (en) 2014-09-16 2016-04-12 Gilead Sciences Inc solid forms of a toll-like receptor modulator
US9573952B2 (en) 2014-09-16 2017-02-21 Gilead Sciences, Inc. Methods of preparing toll-like receptor modulators
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP6704416B2 (en) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Methods for preparing inhibitors of influenza virus replication
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
RU2018112953A (en) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. ACETAMIDTIENOTRIAZOLODIAZODEPINE AND WAYS OF THEIR APPLICATION
PE20181287A1 (en) 2015-09-11 2018-08-07 Dana Farber Cancer Inst Inc CYANE HAS ANOTHRIAZOLPIRAZINES AND USES OF THE SAME
US10751306B2 (en) 2015-11-06 2020-08-25 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
US10913752B2 (en) 2015-11-25 2021-02-09 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibitors and uses thereof
CN105801582A (en) * 2016-04-12 2016-07-27 合肥工业大学 Novel dihydro pteridinone derivative, preparing method thereof and application to medicine
DE102017005091A1 (en) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituted 3,4-dihydropyrido [2,3-b] pyrazine-2 (1H) -one
DE102017005089A1 (en) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituted 3,4-dihydroquinoxaline-2 (1H) -one
CN106977584B (en) * 2017-04-19 2019-12-06 吉林大学 Compound for targeted ubiquitination degradation of PLK1 and BRD4 proteins and application thereof
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
CA3080941A1 (en) * 2017-12-22 2019-06-27 Dana-Farber Cancer Institute, Inc. Nek inhibitors and methods of use
WO2019145410A1 (en) 2018-01-25 2019-08-01 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN110343109B (en) * 2019-08-21 2021-11-23 郑州大学 Dihydropyridone-sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method and application thereof
US20250215101A1 (en) 2022-04-08 2025-07-03 Inhibrx Biosciences, Inc. DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ516872A (en) * 1999-09-15 2003-10-31 Warner Lambert Co Pteridinones as kinase inhibitors
WO2002076985A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
JP3876254B2 (en) * 2001-09-04 2007-01-31 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Novel dihydropteridinone, process for its production and use as a pharmaceutical composition

Also Published As

Publication number Publication date
TW200417369A (en) 2004-09-16
ES2287583T3 (en) 2007-12-16
ATE361924T1 (en) 2007-06-15
HRP20050735A2 (en) 2006-07-31
CN101200457A (en) 2008-06-18
CY1106752T1 (en) 2012-05-23
PT1599478E (en) 2007-05-31
WO2004076454A1 (en) 2004-09-10
MEP58808A (en) 2011-05-10
PL226417B1 (en) 2017-07-31
EA200501222A1 (en) 2006-04-28
CN100537570C (en) 2009-09-09
KR100983462B1 (en) 2010-09-27
CA2517020C (en) 2012-06-26
AU2003215591B2 (en) 2010-06-17
PL378168A1 (en) 2006-03-06
NO332538B1 (en) 2012-10-15
IL170419A (en) 2013-11-28
KR20050113198A (en) 2005-12-01
CA2517020A1 (en) 2004-09-10
HRP20050735B1 (en) 2013-08-31
DE50307267D1 (en) 2007-06-21
TWI313600B (en) 2009-08-21
RS52386B (en) 2013-02-28
NZ542498A (en) 2009-01-31
BR0318145A (en) 2006-02-21
EA008778B1 (en) 2007-08-31
RS20050648A (en) 2007-11-15
ME00376B (en) 2011-10-10
JP3876265B2 (en) 2007-01-31
EP1599478B1 (en) 2007-05-09
SI1599478T1 (en) 2007-10-31
EP1599478A1 (en) 2005-11-30
UA80743C2 (en) 2007-10-25
MXPA05009068A (en) 2005-10-19
AU2003215591A1 (en) 2004-09-17
DK1599478T3 (en) 2007-09-17
JP2006514667A (en) 2006-05-11
HK1089444A1 (en) 2006-12-01
CN1745081A (en) 2006-03-08

Similar Documents

Publication Publication Date Title
NO20054414L (en) Dihydropteridinones, methods for their preparation and their use as medicines
NO20054329L (en) Adamantan derivatives, processes for their preparation, and pharmaceutical compositions which include them
NO20070339L (en) 1-aza-bicyclo [3 3.1] nonanes
NO20081729L (en) New diazaspiroalkanes and their use in the treatment of CCR8-mediated diseases
NO20050828L (en) indole-3-sulfur derivatives
NO20061406L (en) Organic compounds
NO20085176L (en) Phenyl substituted heteroaryl derivatives and use as anti-tumor agents
SE0200920D0 (en) Novel compounds
NO20050635L (en) New tricyclic spiropiperidines or spiropyrrolidines
NO20071504L (en) Pyrimidinderivanter.
NO20054905L (en) 2-acylamino-4-phenylthiazole derivatives, methods for their preparation and use of the same as in therapeutics
TW200621777A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
NO20063787L (en) Therapeutic preparations
NO20060324L (en) [1,8] Naphthyridin-2-ones and related compounds for the treatment of schizophrenia
NO20066055L (en) pyridine derivatives
NO20070570L (en) Compounds.
TW200621262A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
NO20074258L (en) Pyridine-2-carboxamide derivatives as MGLUR5 antagonists
NO20060230L (en) Novel aminobenzophenone compounds
NO20056192L (en) Capase inhibitors and their use
NO20075749L (en) 1H-Quinazoline-2,4-diones and their use as ampa receptor ligands
SE0401762D0 (en) Novel compounds
NO20061363L (en) Pyrazolo and imidazopyrimidine derivatives
NO20063062L (en) Imidazole derivatives, processes for their preparation and use
NO20091766L (en) Spiro-piperidine

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees